Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04406259 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Atrioventricular Block and Cluster Headache (SEVA)

Study acronym: SEVA
StatusActive, Not Recruiting
PhasePhase 4
Started2020-11-02
View on ClinicalTrials.gov ↗

Amendment history

2025-11-25
Recruiting→Active, Not Recruiting Study Status, Contacts/Locations v2
Trial statusRecruiting→Active, Not Recruiting
Primary completion dateestimated 2025-03-01→confirmed 2025-09-05
Completion date2025-03-01→2027-09-05
Study sitesdetails revised at 2 of 2 sites
2023-01-23
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Primary completion date2022-12-01→2025-03-01
Completion date2022-12-01→2025-03-01
Start dateestimated 2020-09-01→confirmed 2020-11-02
Study sites0→2
2020-05-22
Original filing
Verapamil is a calcium channel blocker widely used to treat cardiovascular diseases however it is also the first line treatment in the prevention of cluster headaches. In France, its prescription in that indication is based on compliance with the Temporary Recommendation for Use (RTU) that insists on the possible the cardiac side effects that can occur as the doses required for cluster headache are significantly higher than the doses used in cardiology.
Trial Details
NCT Number NCT04406259
Lead Sponsor Centre Hospitalier Universitaire de Nice
Conditions Cluster Headache
Enrollment 60 participants
Start Date 2020-11-02
Primary Completion 2025-09-05 (estimated)
Study Completion 2027-09-05 (estimated)
Updated on ClinicalTrials.gov 2025-12-02